Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE N/A. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $18M | $34M | $11M | $5M | $43M | $75M | $182M | $518M | $496M | $565M |
| Enterprise Value | $26M | $42M | $60M | $38M | $26M | $50M | $79M | $189M | $526M | $501M | $572M |
| P/E Ratio → | -0.16 | — | 15.71 | 1.69 | — | 30.32 | — | — | 1035.71 | — | — |
| P/S Ratio | 0.07 | 0.60 | 0.96 | 0.25 | 0.13 | 1.06 | 2.55 | 5.37 | 14.54 | 14.23 | 42.01 |
| P/B Ratio | — | — | — | — | — | — | — | 45.72 | 54.87 | 69.73 | 104.30 |
| P/FCF | — | — | — | 25.36 | — | — | 25.41 | 164.03 | — | 86.40 | — |
| P/OCF | — | — | — | 25.36 | — | — | 25.41 | 139.14 | — | 82.07 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.39 | 1.73 | 0.88 | 0.67 | 1.24 | 2.70 | 5.58 | 14.77 | 14.37 | 42.47 |
| EV / EBITDA | — | — | 10.18 | 3.48 | — | 15.65 | — | — | 158.52 | 121.96 | 522.39 |
| EV / EBIT | — | — | 9.54 | 3.49 | — | 18.42 | — | — | 282.60 | 150.04 | — |
| EV / FCF | — | — | — | 89.35 | — | — | 26.94 | 170.64 | — | 87.26 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.8% | 66.8% | 67.9% | 75.0% | 33.7% | 63.5% | 68.9% | 63.1% | 72.4% | 70.7% | 60.6% |
| Operating Margin | -5.9% | -5.9% | 16.7% | 25.3% | -65.0% | 7.7% | -27.1% | -14.5% | 5.1% | 8.4% | 3.6% |
| Net Profit Margin | -40.6% | -40.6% | 6.1% | 14.8% | -85.0% | 3.5% | -31.4% | -18.2% | 1.4% | -2.3% | -56.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | -91.9% | 6.0% | -12.7% | -284.7% |
| ROA | -93.1% | -93.1% | 14.9% | 41.2% | -209.7% | 15.9% | -73.1% | -28.0% | 2.2% | -3.3% | -55.4% |
| ROIC | -24.0% | -24.0% | 88.1% | — | — | 172.5% | -112.9% | -25.7% | 9.3% | 18.6% | 6.3% |
| ROCE | -330.8% | -330.8% | — | — | — | — | -342.7% | -37.1% | 14.5% | 29.5% | 8.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 1.96 | 1.05 | 1.05 | 1.82 |
| Debt / EBITDA | — | — | 4.64 | 2.55 | — | 2.75 | — | — | 3.00 | 1.82 | 9.02 |
| Net Debt / Equity | — | — | — | — | — | — | — | 1.84 | 0.85 | 0.70 | 1.15 |
| Net Debt / EBITDA | — | — | 4.52 | 2.49 | — | 2.22 | — | — | 2.41 | 1.21 | 5.69 |
| Debt / FCF | — | — | — | 63.99 | — | — | 1.52 | 6.61 | — | 0.86 | — |
| Interest Coverage | -1.06 | -1.06 | 1.54 | 2.55 | -4.05 | 2.09 | -7.28 | -4.66 | 1.78 | 2.13 | -6.45 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | 1.22 | 0.93 | 0.84 | 0.61 | 0.85 | 0.50 | 0.86 | 1.46 | 0.60 | 0.60 |
| Quick Ratio | 0.76 | 0.76 | 0.83 | 0.58 | 0.35 | 0.59 | 0.31 | 0.60 | 1.06 | 0.50 | 0.56 |
| Cash Ratio | 0.32 | 0.32 | 0.04 | 0.05 | 0.06 | 0.11 | 0.12 | 0.04 | 0.27 | 0.21 | 0.23 |
| Asset Turnover | — | 2.99 | 2.13 | 3.50 | 2.07 | 3.20 | 5.66 | 1.69 | 1.48 | 1.70 | 0.50 |
| Inventory Turnover | 2.70 | 2.70 | 6.52 | 2.87 | 3.19 | 3.83 | 4.91 | 4.67 | 3.45 | 9.25 | 7.73 |
| Days Sales Outstanding | — | 38.49 | 122.55 | 56.03 | 75.14 | 56.42 | 20.83 | 52.28 | 44.44 | 23.00 | 107.95 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 0.2% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 6.4% | 59.2% | — | 3.3% | — | — | 0.1% | — | — |
| FCF Yield | — | — | — | 3.9% | — | — | 3.9% | 0.6% | — | 1.2% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% |
| Shares Outstanding | — | $10M | $8M | $90M | $90M | $90M | $90M | $90M | $89M | $82M | $69M |
Liquidity exhaustion and insolvency
As reported in recent financial filings, SNYR's P/S ratio of 0.07 suggests the market has largely abandoned the company, pricing it as a collection of declining assets rather than a viable growth platform, which is consistent with its negative TTM P/E of -0.16.
The current valuation multiples indicate that investors are assigning almost zero terminal value to the brand portfolio, likely due to the persistent revenue contraction and inability to achieve scale. This pricing suggests that the market views the company's reliance on high-cost marketing channels as a terminal liability rather than a competitive advantage.
Based on the provided financial data, SNYR's ROIC has collapsed from a peak of 59.5% in 2024Q1 to -27.3% in 2026Q1, illustrating a severe erosion of capital productivity that suggests the company is destroying value with every dollar of reinvestment.
The rapid decay in return on invested capital highlights the failure of the company's acquisition-led strategy to generate sustainable synergies. Investors should monitor whether this trend is a result of declining brand power or an inability to manage the cost structure of its marketing-intensive business model.
According to the company's reported figures, the cash conversion cycle has become increasingly erratic, with DIO reaching 206 days in 2026Q1, suggesting that inventory is becoming a significant drag on liquidity as sales velocity slows across the brand portfolio.
The ballooning inventory days relative to historical levels indicate that the company is struggling to move product through its retail and DTC channels. This inefficiency forces the company to tie up scarce cash in aging stock, further exacerbating the liquidity crunch and limiting the ability to fund necessary marketing spend.
As indicated by the 2026Q1 current ratio of 0.93 and a quick ratio of 0.43, SNYR's liquidity position appears highly vulnerable, leaving the company with minimal flexibility to navigate operational shocks or meet short-term obligations without external capital intervention.
The reliance on inventory to meet current liabilities, as evidenced by the gap between the current and quick ratios, is particularly concerning given the discretionary nature of the company's products. This liquidity profile suggests that any further disruption in sales could lead to an immediate solvency crisis.
Investors frequently misapply traditional healthcare P/E multiples to SNYR, which obscures the reality that the company functions as a media-buying arbitrage firm rather than a pharmaceutical or medical device manufacturer, rendering standard earnings-based valuation metrics largely irrelevant for this business model.
Because SNYR's profitability is entirely dependent on the spread between customer acquisition costs and product margins, analysts should focus on CAC-to-LTV ratios and marketing efficiency metrics instead of P/E. Using traditional healthcare valuation frameworks ignores the structural volatility inherent in the company's reliance on digital and television advertising spend.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNYR stock.
Synergy CHC Corp.'s current P/E ratio is -0.2x. The historical average is 15.9x.
Based on historical data, Synergy CHC Corp. is trading at a P/E of -0.2x. Compare with industry peers and growth rates for a complete picture.
Synergy CHC Corp. has 66.8% gross margin and -5.9% operating margin.